Translational Oncology, Journal Year: 2025, Volume and Issue: 54, P. 102327 - 102327
Published: Feb. 21, 2025
Language: Английский
European Journal of Surgical Oncology, Journal Year: 2023, Volume and Issue: unknown, P. 107064 - 107064
Published: Sept. 1, 2023
Cholangiocarcinoma (CCA) represents a heterogenous set of malignancies arising from the biliary tract. Classification CCA subdivides tumours into intrahepatic (iCCA) and extrahepatic (eCCA), with eCCA further categorised as perihilar (pCCA) distal (dCCA) lesions. Tumour subtypes show distinct epidemiological, genetic clinical characteristics. Global incidence mortality are rising, highest rates seen in Asian populations compared to West. There has been divergence recent trends observed between subtypes, rising iCCA eCCA. several drivers for these differing trends, including specific risk factors, misclassification variation diagnosis surveillance. Risk factors can be divided hepatobiliary, extra-hepatic environmental, hepatobiliary diseases conferring largest risk. Surgery only curative treatment CCA, but offered early-stage candidates who otherwise fit; majority patients therefore treated chemotherapy and, recently, immunotherapy. Due late-stage presentation disease, prognosis is poor, 5-year survival <20%.
Language: Английский
Citations
39
Translational Oncology, Journal Year: 2024, Volume and Issue: 45, P. 101995 - 101995
Published: May 9, 2024
Machine learning has made great progress in the field of medicine, especially oncology research showing significant potential. In this paper, application machine study cholangiocarcinoma was discussed. By developing a novel intra-tumor heterogeneity feature, successfully achieved accurate prediction prognosis and immunotherapy effect patients with cholangiocarcinoma. This not only provides strong support for personalized treatment, but also key information clinicians to develop more effective treatment strategies. breakthrough marks continuous evolution cancer brings new hope future development medical field. Our lays solid foundation deepening understanding biological characteristics improving therapeutic effect, useful reference extensive research.
Language: Английский
Citations
14
Hepatology, Journal Year: 2024, Volume and Issue: 80(6), P. 1462 - 1479
Published: April 12, 2024
Heavy alcohol intake induces a wide spectrum of liver diseases ranging from steatosis, steatohepatitis, cirrhosis, and HCC. Although consumption is well-known risk factor for the development, morbidity, mortality HCC globally, alcohol-associated hepatocellular carcinoma (A-HCC) poorly characterized compared to viral hepatitis–associated Most A-HCCs develop after cirrhosis (AC), but direct carcinogenesis ethanol its metabolites A-HCC remains obscure. The differences between HCCs caused by other etiologies have not been well investigated in terms clinical prognosis, genetic or epigenetic landscape, molecular mechanisms, heterogeneity. Moreover, there huge gap basic research practice due lack preclinical models A-HCC. In current review, we discuss pathogenesis, heterogeneity, approaches, epigenetic, profiles A-HCC, insights into prospects future on potential effect cholangiocarcinoma metastasis also discussed.
Language: Английский
Citations
11
Targeted Oncology, Journal Year: 2024, Volume and Issue: 19(2), P. 213 - 221
Published: Feb. 28, 2024
The combination of gemcitabine and cisplatin (gem/cis) with the anti-PD-L1-antibody durvalumab was recently approved as first line therapy for biliary tract cancer (BTC) based on results TOPAZ-1 trial. We aim to analyse feasibility efficacy triple in patients BTC a real-world setting correspondence genetic alterations cancer. In this single-centre retrospective analysis, all treated plus gem/cis from April 2022 September 2023 were included. Survival treatment response investigated, within context inclusion exclusion criteria total, 35 patients, which 51% met trial, analysed. Patients did not have significantly different median overall survival progression free than rest (10.3 versus 9.7 months 5.3 5 months, respectively). disease control rate 61.1%, comparison 58.8% patients. A total 51 grade 3 4 adverse events observed without significant differences subgroups. No specific correlating patterns observed. advanced gem/cis, even beyond shows promising safety.
Language: Английский
Citations
9
Journal of Translational Medicine, Journal Year: 2025, Volume and Issue: 23(1)
Published: Jan. 9, 2025
Language: Английский
Citations
1
Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14
Published: Feb. 23, 2024
Gastrointestinal (GI) tumors are a significant global health threat, with high rates of morbidity and mortality. Exosomes contain various biologically active molecules like nucleic acids, proteins, lipids can serve as messengers for intercellular communication. They play critical roles in the exchange information between tumor cells microenvironment (TME). The TME consists mesenchymal components extracellular matrix (ECM), fibroblasts being most abundant cell type mesenchyme. Cancer-associated (CAFs) derived from normal stem that activated TME. CAFs secrete exosomes to modulate proliferation, invasion, migration, drug resistance, other biological processes tumors. Additionally, manipulate function behavior through direct cell-cell interactions. This review provides summary crosstalk GI exosomes, along potential underlying mechanisms.
Language: Английский
Citations
8
Cancer Medicine, Journal Year: 2024, Volume and Issue: 13(3)
Published: Jan. 11, 2024
Abstract Background Current standard of care for advanced biliary tract cancer (BTC) is gemcitabine, cisplatin plus anti‐PD1/PD‐L1, but response rates are modest. The purpose this study was to explore the efficacy and safety durvalumab (anti‐PD‐L1) tremelimumab (anti‐CTLA‐4), with without an interventional radiology (IR) procedure in BTC. Methods Eligible patients BTC who had received or refused at least one prior line systemic therapy were treated four combined doses followed by monthly alone IR until progression disease unacceptable toxicity. Objective assessed through CT MRI Response Evaluation Criteria Solid Tumors (RECIST, version 1.1) every 8 weeks. Adverse events (AEs) recorded managed. primary endpoint 6‐month progression‐free survival (PFS). Results Twenty‐three enrolled; 17 assigned treatment (Durva/Treme); 6 combination durvalumab, (Durva/Treme + IR). best clinical responses Durva/Treme arm partial ( n = 1), stable 5), progressive arm: 0), 3), 3). median PFS 2.2 months (95% CI: 1.3–3.1 months) 2.9 1.9–4.7 p 0.27). OS 5.1 2.5–6.9 5.8 2.9–40.1 0.31). majority AEs grades 1–2. Conclusion showed similar efficacy. With a manageable profile. Larger studies needed fully characterize ±
Language: Английский
Citations
6
Cancer Cell International, Journal Year: 2024, Volume and Issue: 24(1)
Published: March 2, 2024
Abstract Background Cholangiocarcinoma represents a malignant neoplasm originating from the hepatobiliary tree, with subset of tumors developing inside liver. Intrahepatic cholangiocarcinomas (ICC) commonly exhibit an asymptomatic presentation, rendering both diagnosis and treatment challenging. Cuproptosis, emerging regulated cell death pathway induced by copper ions, has garnered attention recently. As cancer cells show altered metabolism comparatively higher needs, cuproptosis may play role in development ICC. However, studies investigating this possibility are currently lacking. Methods Single-cell bulk RNA sequence data were analyzed, correlations established between expression cuproptosis-related molecules ICC patient survival. Genes predicting survival used to create CUPT score using Cox LASSO regression tumor mutation burden (TMB) analysis. The CIBERSORT software was employed characterize immune infiltration within tumors. Furthermore, prediction, biological function enrichment, drug sensitivity analyses conducted explore potential implications signature. effects silencing solute carrier family 39 member 4 gene (SLC39A4) siRNA investigated assays measuring proliferation, colony formation, migration. Key genes detected western blotting. Results developed divided patients into high low groups. Those had significantly better prognosis longer In contrast, scores associated worse clinical outcomes TMB. Comparisons two groups also indicated differences infiltrate present Finally, we able identify 95 drugs potentially affecting pathway. Some these might be effective vitro experiments revealed that suppressing SLC39A4 lines resulted reduced It led increase upregulation key cuproptosis, namely ferredoxin 1 (FDX1) dihydrolipoyl transacetylase (DLAT). These findings strongly suggest cuproptosis-associated molecule pivotal metastasis Conclusions Changes signature can predict considerable accuracy. This supports notion influences diversity complexity microenvironment, mutational landscape, behavior Understanding hold promise for innovative strategies management disease.
Language: Английский
Citations
6
Cancer Letters, Journal Year: 2024, Volume and Issue: 588, P. 216799 - 216799
Published: March 11, 2024
As two major types of primary liver cancers, the tumor immune microenvironment (TIME) hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) have been well studied separately. However, a systemic assessment similarities differences between TIME HCC ICC is still lacking. In this study, we pictured landscape combined by sequencing integrating 41 single-cell RNA-seq samples from four different tissue both malignancies. We found that T cells in tumors generally exhibit higher levels immunosuppression exhaustion than those tumors. Myeloid also distinct phenotypes may serve as key factor driving their TIMEs. Besides, identified cluster EGR1+ macrophages specifically enriched Together, our study provides new insights into cellular composition, states interactions TIMEs ICC, which could pave way for development future therapeutic targets cancers.
Language: Английский
Citations
6
Nutrients, Journal Year: 2023, Volume and Issue: 15(14), P. 3090 - 3090
Published: July 10, 2023
Cholangiocarcinoma (CCA) is an aggressive cancer associated with a very poor prognosis and low survival rates, primarily due to late-stage diagnosis response rates conventional chemotherapy. Therefore, there urgent need identify effective therapeutic strategies that can improve patient outcomes. Flavonoids, such as quercetin kaempferol, are naturally occurring compounds have attracted significant attention for their potential in therapy by targeting multiple genes. In this study, we employed network pharmacology bioinformatic analysis targets of kaempferol. The results revealed the target genes these flavonoids were enriched G2/M-related genes, higher expression G2/M signature was significantly shorter CCA patients. Furthermore, vitro experiments using cells demonstrated or kaempferol induced cell-cycle arrest phase. Additionally, when combined Smac mimetic LCL-161, IAP antagonist, synergistically RIPK1/RIPK3/MLKL-mediated necroptosis while sparing non-tumor cholangiocyte cells. These findings shed light on innovative combination flavonoids, particularly mimetics, suggesting great promise necroptosis-based approach treating potentially other types cancer.
Language: Английский
Citations
13